Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 10, 2008, Pages 3776-3778

  Waites, Ken B ^a   Crabb, Donna M ^a   Duffy, Lynn B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; DC 159A; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; MYCOPLASMA FERMENTANS; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; UREAPLASMA; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM;

AMINOPYRIDINES; ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA; MYCOPLASMA FERMENTANS; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; UREAPLASMA; UREAPLASMA INFECTIONS;

EID: 54049091574     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00849-08     Document Type: Article

References (11)

1. Bebear, C. M., H. Renaudin, A. Boudjadja, and C. Bebear. 1998. In vitro activity of BAY-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob. Agents Chemother. 42:703-704.
2. Duffy, L., J. Glass, G. Hall, R. Avery, R. Rackley, S. Peterson, and K. Waites. 2006. Fluoroquinolone resistance in Ureaplasma parvum in the United States. J. Clin. Microbiol. 44:1590-1591.
3. Duffy, L. B., D. M. Crabb, X. Bing, and K. B. Waites. 2003. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J. Antimicrob. Chemother. 52:527-528.
4. Hoshino, K., K. Inoue, Y. Murakami, Y. Kurosaka, K. Namba, Y. Kashimoto, S. Uoyama, R. Okumura, S. Higuchi, and T. Otani. 2008. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob. Agents Chemother. 52:65-76.
5. Hoshino, K., R. Okumura, K. Inoue, Y. Murakami, and H. Awaya. 2006. DC-159a, a new generation of respiratory quinolone: in vitro activities against clinical isolates and its mode of action against topoisomerases, abstr. F1-0478. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
6. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2006. DC-159a, a novel oral quinolone, activity tested against community-acquired respiratory tract (CARTI) pathogens, abstr. F1-0480. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
7. Kenny, G. E., and F. D. Cartwright. 2001. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45:2604-2608.
8. Waites, K. B. 2001. Mycoplasma, p. 649-655. In D. Schlossberg (ed.), Current therapy of infectious disease, 2nd ed. Mosby-Year Book, Inc., St. Louis, MO.
9. Waites, K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47:161-165.
10. Waites, K. B., L. B. Duffy, S. Schwartz, and D. F. Talkington. 2004. Mycoplasma and Ureaplasma, p. 3.15.1-3.15.15. In H. Isenberg (ed.), Clinical microbiology procedures handbook, 2nd ed. ASM Press, Washington, DC.
11. Waites, K. B., and D. Taylor-Robinson. 2007. Mycoplasma and Ureaplasma, p. 1004-1020. In P. R. Murray, E. J. Baron, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.